Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy
- PMID: 11731878
- DOI: 10.1007/s100720100021
Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy
Abstract
In order to identify early clinical features and survival predictors of supranuclear palsy (PSP) and multiple system atrophy (MSA), we compared the disease course of patients consecutively referred between 1987 and 1999 and followed to December 1999. Thirty-nine PSP and 74 MSA patients were diagnosed according to commonly accepted clinical criteria. Length of survival was ascertained from death certificates or by contacting relatives. Ten-year survival after disease onset was 29% for both disorders. Median survival was 7.0 years (PSP) and 7.5 (MSA). Neither age, symptoms at onset, or disability at diagnosis predicted survival. At diagnosis, all PSP patients had oculomotor palsy, whereas 89% of MSA patients had dysautonomia; bradykinesia and falls were the most frequent common signs. Distinctive early signs were palilalia, cognitive impairment and hyperreflexia in PSP; hypophonia, anterocollis and dysautonomia in MSA. MSA patients responded better to levodopa. Attention to early distinctive features can improve differential diagnosis and inform subsequent management.
Similar articles
-
Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.Parkinsonism Relat Disord. 2013 Dec;19(12):1149-51. doi: 10.1016/j.parkreldis.2013.07.019. Epub 2013 Aug 3. Parkinsonism Relat Disord. 2013. PMID: 23916652
-
Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.J Neurol Neurosurg Psychiatry. 1996 Jun;60(6):615-20. doi: 10.1136/jnnp.60.6.615. J Neurol Neurosurg Psychiatry. 1996. PMID: 8648326 Free PMC article.
-
Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.J Neurol. 2014 Aug;261(8):1575-83. doi: 10.1007/s00415-014-7384-x. Epub 2014 Jun 3. J Neurol. 2014. PMID: 24888315
-
Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy.Continuum (Minneap Minn). 2019 Aug;25(4):919-935. doi: 10.1212/CON.0000000000000751. Continuum (Minneap Minn). 2019. PMID: 31356287 Review.
-
Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy.Parkinsonism Relat Disord. 2017 Jan;34:7-14. doi: 10.1016/j.parkreldis.2016.10.013. Epub 2016 Oct 19. Parkinsonism Relat Disord. 2017. PMID: 28341224 Review.
Cited by
-
Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.EPMA J. 2010 Jun;1(2):305-16. doi: 10.1007/s13167-010-0029-y. Epub 2010 Jun 12. EPMA J. 2010. PMID: 23199066 Free PMC article.
-
Epidemiology of atypical parkinsonian syndromes.Tzu Chi Med J. 2021 Jan 19;34(2):169-181. doi: 10.4103/tcmj.tcmj_218_20. eCollection 2022 Apr-Jun. Tzu Chi Med J. 2021. PMID: 35465274 Free PMC article. Review.
-
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.J Neurol. 2016 Aug;263(8):1565-74. doi: 10.1007/s00415-016-8169-1. Epub 2016 May 26. J Neurol. 2016. PMID: 27230855 Clinical Trial.
-
Factors that impact dysphagia and discontinuance of oral intake in patients with progressive supranuclear palsy.Front Neurol. 2023 Sep 13;14:1259327. doi: 10.3389/fneur.2023.1259327. eCollection 2023. Front Neurol. 2023. PMID: 37780702 Free PMC article.
-
Grand Total EEG Score Can Differentiate Parkinson's Disease From Parkinson-Related Disorders.Front Neurol. 2019 Apr 18;10:398. doi: 10.3389/fneur.2019.00398. eCollection 2019. Front Neurol. 2019. PMID: 31057481 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous